Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIFC1 | Q9BW19 | 5/20 | 0.60 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.58 |
| ▸ | ITGA4 | P13612 | 6/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.56 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.53 |
| ▸ | FPR2 | P25090 | 1/20 | 0.53 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8337586 | 0.91 | ITGB1 (0.66) | KIFC1ITGB1ITGA4MCL1ITGB7 | |
| SCHEMBL5927201 | 0.89 | ITGB1 (0.66) | KIFC1ITGB1ITGA4MCL1ITGB7 | |
| SCHEMBL5692210 | 0.88 | ITGB1 (0.56) | KIFC1ITGB1ITGA4ITGB7PDK1 | |
| SCHEMBL5926920 | 0.86 | PDK1 (0.56) | KIFC1ITGB1ITGA4MCL1ITGB7 | |
| SCHEMBL5927352 | 0.86 | KIFC1 (0.61) | KIFC1ITGB1ITGA4MCL1ITGB7 | |
| SCHEMBL5927166 | 0.84 | PDK1 (0.54) | KIFC1ITGB1ITGA4MCL1FPR2 | |
| SCHEMBL6097133 | 0.84 | ITGB1 (0.51) | KIFC1ITGB1ITGA4MCL1ITGB7 | |
| SCHEMBL3991301 | 0.84 | ITGB1 (0.51) | KIFC1ITGB1ITGA4MCL1ITGB7 | |
| SCHEMBL4829787 | 0.84 | ITGB1 (0.51) | KIFC1ITGB1ITGA4MCL1ITGB7 | |
| SCHEMBL3989525 | 0.84 | ITGB1 (0.51) | KIFC1ITGB1ITGA4MCL1ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | KIFC1 4489/4885ITGB1 240/4885ITGA4 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.